Skip to main content
SpringerLink
Log in

Clinical Studies and Practice

Omentin-1 levels are reduced by pharmacologic doses of leptin, but remain unaffected by energy deprivation and display no day–night variation

  • Original Article
  • Published:
International Journal of Obesity Submit manuscript

Abstract

Objective:

To study the day–night variation of omentin-1 levels and assess whether leptin and/or short- and long-term energy deprivation alter circulating omentin-1 levels via cytokines.

Design and methods:

Omentin-1 levels were measured hourly in serum samples from six healthy men to evaluate for day–night variation. To study effects of acute energy deprivation and of leptin administration, eight healthy subjects were studied in the fasting state for 72 h with administration of either placebo or metreleptin (recombinant human leptin) in physiologic replacement doses. We evaluated the effect of leptin in pharmacologic doses on serum omentin-1 and cytokine levels, as well as on omentin-1 levels in ex vivo omental adipose tissue, in 15 healthy volunteers. To study the effect of chronic energy deprivation and weight loss on omentin-1 levels, we followed 18 obese subjects for 12 months who underwent bariatric surgery.

Results:

There is no day–night variation in omentin-1 levels. Short-term and chronic energy deprivation, as well as ex vivo leptin administration and physiologic replacement doses of leptin, do not alter omentin-1 levels; pharmacologic doses of metreleptin reduce omentin-1 levels, whereas levels of tumor necrosis factor-α receptor II and interleukin-6 tend to increase.

Conclusions:

Omentin-1 levels are reduced by pharmacologic doses of metreleptin independent of effects on cytokine levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Liu J, Fox CS, Hickson D, Bidulescu A, Carr JJ, Taylor HA . Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler Thromb Vasc Biol 2011; 31: 2715–2722.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Liu J, Fox CS, Hickson DA, May WD, Hairston KG, Carr JJ et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. J Clin Endocrinol Metab 2010; 95: 5419–5426.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–48.

    Article  PubMed  Google Scholar 

  4. Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, Buchler C . Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005; 1732: 96–102.

    Article  CAS  PubMed  Google Scholar 

  5. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253–E1261.

    Article  CAS  PubMed  Google Scholar 

  6. Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, Lehnert H et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801–808.

    Article  CAS  PubMed  Google Scholar 

  7. Barth S, Klein P, Horbach T, Dotsch J, Rauh M, Rascher W et al. Expression of neuropeptide Y, omentin and visfatin in visceral and subcutaneous adipose tissues in humans: relation to endocrine and clinical parameters. Obesity Facts 2010; 3: 245–251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Auguet T, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011; 12: 60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Fain JN, Sacks HS, Buehrer B, Bahouth SW, Garrett E, Wolf RY et al. Identification of omentin mRNA in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes 2008; 32: 810–815.

    Article  CAS  Google Scholar 

  10. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655–1661.

    Article  CAS  PubMed  Google Scholar 

  11. Shibata R, Takahashi R, Kataoka Y, Ohashi K, Ikeda N, Kihara S et al. Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men. Hypertens Res 2011; 34: 1309–1312.

    Article  CAS  PubMed  Google Scholar 

  12. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM . Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity 2011; 19: 1552–1559.

    Article  CAS  PubMed  Google Scholar 

  13. Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W, Fruhbeck G et al. Circulating omentin concentration increases after weight loss. Nutr Metab 2010; 7: 27.

    Article  Google Scholar 

  14. Saremi A, Asghari M, Ghorbani A . Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci 2010; 28: 993–998.

    Article  CAS  PubMed  Google Scholar 

  15. El-Mesallamy HO, El-Derany MO, Hamdy NM . Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med 2011; 28: 1194–1200.

    Article  CAS  PubMed  Google Scholar 

  16. Pan HY, Guo L, Li Q . Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010; 88: 29–33.

    Article  CAS  PubMed  Google Scholar 

  17. Choi JH, Rhee EJ, Kim KH, Woo HY, Lee WY, Sung KC . Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol 2011; 165: 789–796.

    Article  CAS  PubMed  Google Scholar 

  18. Liu R, Wang X, Bu P . Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011; 93: 21–25.

    Article  CAS  PubMed  Google Scholar 

  19. Yan P, Liu D, Long M, Ren Y, Pang J, Li R . Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 257–263.

    Article  CAS  PubMed  Google Scholar 

  20. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y . Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010; 393: 668–672.

    Article  CAS  PubMed  Google Scholar 

  21. Van de Voorde J, Pauwels B, Boydens C, Decaluwe K . Adipocytokines in relation to cardiovascular disease. Metabolism 2013; 62: 1513–1521.

    Article  CAS  PubMed  Google Scholar 

  22. Brunetti L, Orlando G, Ferrante C, Recinella L, Leone S, Chiavaroli A et al. Orexigenic effects of omentin-1 related to decreased CART and CRH gene expression and increased norepinephrine synthesis and release in the hypothalamus. Peptides 2013; 44: 66–74.

    Article  CAS  PubMed  Google Scholar 

  23. Brunetti L, Di Nisio C, Recinella L, Chiavaroli A, Leone S, Ferrante C et al. Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat. Peptides 2011; 32: 1866–1871.

    Article  CAS  PubMed  Google Scholar 

  24. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H . Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012; 686: 116–123.

    Article  CAS  PubMed  Google Scholar 

  25. Zhong X, Li X, Liu F, Tan H, Shang D . Omentin inhibits TNF-alpha-induced expression of adhesion molecules in endothelial cells via ERK/NF-kappaB pathway. Biochem Biophys Res Commun 2012; 425: 401–406.

    Article  CAS  PubMed  Google Scholar 

  26. Yamawaki H . Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011; 34: 307–310.

    Article  CAS  PubMed  Google Scholar 

  27. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y . Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011; 408: 339–343.

    Article  CAS  PubMed  Google Scholar 

  28. Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS . The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 2003; 111: 1409–1421.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kershaw EE, Flier JS . Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548–2556.

    Article  CAS  PubMed  Google Scholar 

  30. Montague CT, Prins JB, Sanders L, Digby JE, O'Rahilly S . Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997; 46: 342–347.

    Article  CAS  PubMed  Google Scholar 

  31. Batra A, Okur B, Glauben R, Erben U, Ihbe J, Stroh T et al. Leptin: a critical regulator of CD4+ T-cell polarization in vitro and in vivo. Endocrinology 2010; 151: 56–62.

    Article  CAS  PubMed  Google Scholar 

  32. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS . Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010; 59: 3023–3031.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Shaker M, Mashhadani ZI, Mehdi AA . Effect of treatment with metformin on omentin-1, ghrelin and other biochemical, clinical features in PCOS patients. Oman Med J 2010; 25: 289–293.

    PubMed  PubMed Central  Google Scholar 

  34. Korner J, Punyanitya M, Taveras C, McMahon DJ, Kim HJ, Inabnet W et al. Sex differences in visceral adipose tissue post-bariatric surgery compared to matched non-surgical controls. Int J Body Compos Res 2008; 6: 93–99.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Part of the results described herein was presented at Endo 2012 in Houston, TX, USA in June 2012. The Mantzoros group was supported by the National Institute of Diabetes and Digestive and Kidney Diseases Grants 58785, 79929 and 81913. The project described was also supported by Award Number 1I01CX000422-01A1 from the Clinical Science Research and Development Service of the VA Office of Research and Development. Amylin Pharmaceuticals LLC, supplied metreleptin for this study and approved the design of the study but had no role in the study design; conduct of the study; collection, management, analysis and interpretation of the data; or the preparation, review or approval of the manuscript. This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award No. UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health-care centers). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health-care centers, or the National Institutes of Health.

Author information

Author notes

  1. O-PR Hamnvik and B Thakkar: These authors contributed equally to this work.

Authors and Affiliations

  1. Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    O-PR Hamnvik

  2. Section of Endocrinology, Veteran’s Affairs Boston Healthcare System, Harvard Medical School, Boston, MA, USA

    O-PR Hamnvik, B Thakkar, J Chamberland & C S Mantzoros

  3. Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA

    B Thakkar

  4. Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    B Thakkar, J Chamberland, K Aronis & C S Mantzoros

  5. Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    B Schneider

Authors
  1. O-PR Hamnvik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Thakkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Chamberland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Aronis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C S Mantzoros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C S Mantzoros.

Ethics declarations

Competing interests

Dr CS Mantzoros has received research support for investigator-initiated trials from Amylin Pharmaceuticals LLC (a wholly-owned subsidiary of Bristol-Myers Squibb) through Beth Israel Deaconess Medical Center. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamnvik, OP., Thakkar, B., Chamberland, J. et al. Omentin-1 levels are reduced by pharmacologic doses of leptin, but remain unaffected by energy deprivation and display no day–night variation. Int J Obes 39, 260–264 (2015). https://doi.org/10.1038/ijo.2014.106

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2014.106

  • Springer Nature Limited

Search

Navigation